Korro Bio, Inc.
Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria
Korro Bio (Nasdaq: KRRO) said it granted non-statutory stock options to seven newly hired employees under its 2026 Inducement Plan. Four employees received options for 6,000 shares total at $10.59 per share (June 10, 2026 close), and three received options for 17,000 shares total at $14.72 (July 8, 2026 close). Options vest over four years.
FORMELA JEAN FRANCOIS sold 110,023 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.02 ($13.96–$14.03, $1.54M total) across 4 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning KRRO (Korro Bio, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KRRO coverage spans insider activity, corporate actions and financial news.
In the last 30 days, KRRO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($63K). The most active reporter was Aiyar Ram, President and CEO, with 1 filing.
Near-term catalyst is regulatory progress to start KRRO-121 clinical trials in 2H26, supported by EMA orphan designation and added pipeline (KRRO-111).
This is a routine equity-inducement grant with disclosed strike prices and vesting terms, implying modest dilution/overhang but no fundamental reset.
This is an insider sale disclosure; it may modestly affect sentiment but does not change fundamentals by itself.
This is a routine insider-sale disclosure; it may slightly affect sentiment but does not indicate a new fundamental catalyst by itself.
This is a corporate governance/meeting-results disclosure; it typically has limited fundamental impact but can affect near-term sentiment around board/management continuity.
alphai scores every news story that mentions KRRO with an AI model for sentiment and relevance, and aggregates insider trades from Korro Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria
6 min readKorro Bio (Nasdaq: KRRO) said it granted non-statutory stock options to seven newly hired employees under its 2026 Inducement Plan. Four employees received options for 6,000 shares total at $10.59 per share (June 10, 2026 close), and three received options for 17,000 shares total at $14.72 (July 8, 2026 close). Options vest over four years.
2 min readFORMELA JEAN FRANCOIS sold 110,023 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.02 ($13.96–$14.03, $1.54M total) across 4 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.
2 min readFORMELA JEAN FRANCOIS sold 171,405 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.34 ($13.95–$14.98, $2.46M total) across 8 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.
2 min readKorro Bio, Inc. (KRRO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001703647 NASDAQ 0001703647 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event report ed): J
2 min readAiyar Ram (President and CEO) sold 15,152 shares of Korro Bio, Inc. (KRRO) at $12.98 ($0.20M total) on 2026-05-29.
2 min readFORMELA JEAN FRANCOIS sold 419 indirectly-held shares of Korro Bio, Inc. (KRRO) at $13.95 on 2026-05-28 under a Rule 10b5-1 trading plan.
1 min readFORMELA JEAN FRANCOIS sold 2,441 indirectly-held shares of Korro Bio, Inc. (KRRO) at $13.95 on 2026-05-28 under a Rule 10b5-1 trading plan.
2 min readLynx1 Master Fund LP, associated with Lynx1 Capital Management LP and Weston Nichols, has purchased 520 shares of Korro Bio, Inc. (KRRO) common stock at $10.60 per share, as reported in a recent SEC Form 4 filing. This transaction brings their indirect holdings to 1,538,296 shares. Both Lynx1 Capital Management LP and Weston Nichols disclaim beneficial ownership except for any pecuniary interest.
2 min readKorro Bio reported a widening net loss in 2025 to $117.3 million, up from $83.6 million in 2024, despite an increase in collaboration revenue and progress in its RNA-editing pipeline. The company nominated KRRO-121 as a development candidate for hyperammonemia and advanced its alpha-1 antitrypsin deficiency program. An $85 million private placement in March 2026 is expected to extend Korro Bio's cash runway into the second half of 2028.
3 min read
